Search

Search Results

1. Role of Calcitonin and Strontium Ranelate in Osteoporosis

   Background

   Both Strontium Ranelate (SR) and Calcitonin (CT) can be used to treat osteoporosis. Calcitonin was actually one of the very initial...

   Abdul Ghani, Sakib Arfee in Indian Journal of Orthopaedics

   Article 04 December 2023

2. Cardiovascular safety of calcium, magnesium and strontium: what does the evidence say?

   Calcium, magnesium and strontium have all been implicated in both musculoskeletal and cardiovascular health and disease. However, despite these three...

   Elizabeth M. Curtis, Cyrus Cooper, Nicholas C. Harvey in Aging Clinical and Experimental Research

   Article Open access 09 February 2021
   

3. Osteoporosis Prevention and Management

   Osteoporosis, defined by BMD at the hip or lumbar spine that is less than or equal to 2.5 standard deviations below the mean BMD of a young-adult...

   Muralidhar V. Pai in The Journal of Obstetrics and Gynecology of India

   Article 20 April 2017

4. Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology

   Background

   The Italian Society for Orthopaedics and Traumatology conceived this guidance—which is primarily addressed to Italian orthopedic surgeons,...

   Umberto Tarantino, Giovanni Iolascon, ... Maria Luisa Brandi in Journal of Orthopaedics and Traumatology

   Article Open access 20 October 2017
   

5. Increased risk of strontium ranelate-related SJS/TEN is associated with HLA

   Summary

   Severe adverse drug reactions (ADR) of Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) in some patients receiving strontium...

   H. Y. Lee, M. X. Shen, ... E. C. Ren in Osteoporosis International

   Article 22 March 2016

6. Effect of osteoporosis medications on fracture healing

   Antiosteoporotic medications are often used to concurrently treat a patient’s fragility fractures and underlying osteoporosis. This review evaluates...

   V. Hegde, J. E. Jo, ... J. M. Lane in Osteoporosis International

   Article 29 September 2015

7. 7th drug hypersensitivity meeting: part one

   Oral Abstracts

   O1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TEN

   Daniel F. Carr, Wen-Hung Chung,...

   Daniel F. Carr, Wen-Hung Chung, ... Francisco Javier Ruano in Clinical and Translational Allergy

   Article Open access 25 August 2016
   

8. The calcium-sensing receptor in bone metabolism: from bench to bedside and back

   Summary

   The calcium-sensing receptor (CaSR), a key player in the maintenance of calcium homeostasis, can influence bone modeling and remodeling by...

   L. Cianferotti, A. R. Gomes, ... M. L. Brandi in Osteoporosis International

   Article 23 June 2015
   

9. The Future of Osteoarthritis Therapeutics: Targeted Pharmacological Therapy

   Osteoarthritis (OA) is one of the most common forms of degenerative joint disease and a major cause of pain and disability affecting the aging...

   A. Mobasheri in Current Rheumatology Reports

   Article Open access 24 September 2013
   

10. Fracture healing in elderly patients: new challenges for antiosteoporotic drugs

    Osteoporosis is a major public health concern, characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility...

    Umberto Tarantino, Luca Saturnino, ... Pietro Pistillo in Aging Clinical and Experimental Research

    Article 02 August 2013
    

11. Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate

    Summary

    We have reviewed 47 drug rash with eosinophilia and systemic symptoms (DRESS) cases associated to strontium ranelate reported up to March 2011...

    P. Cacoub, V. Descamps, ... P. Musette in Osteoporosis International

    Article 30 January 2013
    

12. Alopecia associated with strontium ranelate use in a 62-year-old woman

    Strontium ranelate is an effective drug that was developed for treating osteoporosis. Here, we report the case of a 62-year-old woman who developed...

    Y.-Y. Lee, C.-H. Yang, ... J.-S. Hwang in Osteoporosis International

    Article 12 April 2012
    

13. European guidance for the diagnosis and management of osteoporosis in postmenopausal women

    Summary

    Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis.

    ...

    J. A. Kanis, E. V. McCloskey, ... J.-Y. Reginster in Osteoporosis International

    Article Open access 19 October 2012
    

14. Effective use of strontium-89 in osseous metastases

    Bone is one of the organs to which cancer metastasizes most frequently. However, it is not a vital organ, therefore, survival after the occurrence of...

    Isao Kuroda in Annals of Nuclear Medicine

    Article 13 December 2011
    

15. Strontium ranelate

    in Reactions Weekly

    Article 01 July 2011

16. Spotlight on Strontium Ranelate

    This is a review of the pharmacology of strontium ranelate (Protelos®, Protos®, Protaxos®, Bivalos®, Osseor®), and its efficacy and tolerability in...

    Emma D. Deeks, Sohita Dhillon in Drugs & Aging

    Article 01 September 2010

17. Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis

    Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of...

    Jean-Yves Reginster in Drugs

    Article 01 January 2011
    

18. Possible benefits of strontium ranelate in complicated long bone fractures

    Osteoporosis drugs are prescribed to prevent fragility fractures, which is the principal aim of the management of osteoporosis. However, if fracture...

    Duarte Nuno Alegre, Costa Ribeiro, ... Luís de Almeida in Rheumatology International

    Article 01 December 2010
    

19. Strontium Ranelate

    This is a review of the pharmacology of strontium ranelate (Protelos®, Protos®, Protaxos®, Bivalos®, Osseor®), and its efficacy and tolerability in...

    Emma D. Deeks, Sohita Dhillon in Drugs

    Article 01 April 2010
    

20. Anabolic Agents and Bone Quality

    Background

    The definition of bone quality is evolving particularly from the perspective of anabolic agents that can enhance not only bone mineral...

    Tarek Sibai, Elise F. Morgan, Thomas A. Einhorn in Clinical Orthopaedics and Related Research®

    Article 04 December 2010